Sign In
Buy GSK
$51.46
-0.0700 (-0.136%)
At Close: Aug 05, 2026
Pfizer wins bid to invalidate GSK's patents over RSV vaccine
06:26am, Monday, 07'th Oct 2024
Pfizer on Monday won a bid in a London court to invalidate two of GSK's patents relating to a respiratory syncytial virus (RSV) vaccine.
Sanofi, GSK, CSL tapped to expand US bird flu vaccine supply, Bloomberg News reports
09:08am, Friday, 04'th Oct 2024
GSK , Sanofi and CSL Ltd have secured $72 million from the U.S. government to ramp up production of bird flu vaccines, Bloomberg News reported on Friday.
GSK: Does RSV jab work too well?
04:48am, Tuesday, 01'st Oct 2024
GSK PLC's respiratory syncytial virus (RSV) vaccine, Arexvy, faces challenges that could impact its financial future, according to a report by Jefferies. The jab is designed to protect older adults
3 'Repeatable' Biotech Trades
12:46pm, Wednesday, 25'th Sep 2024
Small-cap biotech stocks have struggled over the past five years, but lower interest rates may boost sentiment and M&A activity, benefiting the sector. One way I have kept my biotech portfolio churnin
Why GSK (GSK) is a Top Value Stock for the Long-Term
10:47am, Monday, 23'rd Sep 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
GSK Meets Study Goal for Co-Administered RSV-Shingles Vaccines
02:01pm, Thursday, 19'th Sep 2024
Data from a late-stage study shows that co-administering GSK's RSV and Shingles vaccines together was as effective as giving each separately.
GSK settles two California lawsuits related to heartburn drug Zantac
09:19am, Wednesday, 18'th Sep 2024
British drugmaker GSK said on Wednesday it had agreed to settle two lawsuits in California that claimed its discontinued heartburn drug Zantac caused cancer.
GSK's RSV vaccine meets main goal when co-administered with shingles shot
07:34am, Wednesday, 18'th Sep 2024
British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles shot, met the main goal of a late-stage trial in adults over 50 years of ag
GSK Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX
07:00am, Wednesday, 18'th Sep 2024
PHILADELPHIA--(BUSINESS WIRE)-- #Adult--GSK announces positive topline data on co-administration of AREXVY and SHINGRIX.
Brooke Shields Partners with GSK to Educate Adults 50 and Older About Their Shingles Risk
01:04pm, Monday, 16'th Sep 2024
Brooke Shields convenes other celebrities, influencers and patient advocates over 50 to discuss the power of aging and how to protect their health Shields directs a short film, encouraging adults 50 y
Kalm Therapeutics Hires Former GSK Director Dr. Tomoko Maeda-Chubachi as Chief Medical Officer
08:00am, Monday, 16'th Sep 2024
Huntsville, Alabama--(Newsfile Corp. - September 16, 2024) - Kalm Therapeutics (Kalm Tx) is pleased to announce the appointment of Dr. Tomoko Maeda-Chubachi, M.D., Ph.D., as our Chief Medical Officer.
GSK cancer drugs fast-tracked by Chinese
03:05am, Friday, 13'th Sep 2024
GSK PLC (LSE:GSK, NYSE:GSK) announced that its blood cancer drug Blenrep (belantamab mafodotin), in combination with two current treatments, has received Breakthrough Therapy Designation (BTD) in Chin
GSK's HSV Vaccine Study Fails to Meet Primary Efficacy Goal
12:41pm, Thursday, 12'th Sep 2024
The phase I/II proof-of-concept study evaluating GSK's herpes simplex virus vaccine candidate, GSK3943104, fails to meet the primary efficacy objective.
CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program
07:15am, Thursday, 12'th Sep 2024
Phase 2 data demonstrated positive immune responses to A and B strains, with acceptable safety and reactogenicity profile, meeting all pre-defined study endpoints Vaccine candidate based on CureVac's
GSK enjoys success with mRNA flu vaccine trial
03:43am, Thursday, 12'th Sep 2024
GSK PLC (LSE:GSK, NYSE:GSK) has been encouraged by the initial results of a seasonal flu vaccine using mRNA technology. Following disappointing tests for its vaccine division earlier in the week with
